Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study
Ryota Saito(Tohoku University), Kunihiko Kobayashi(Saitama International Medical Center), Ryo Ko(Shizuoka Cancer Center), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Hiroshi Kagamu(Saitama International Medical Center), Kenji Sugio(University of Occupational and Environmental Health Japan), Toshiaki Kikuchi(Tohoku University), Satoshi Oizumi(Hokkaido University), Koichi Azuma(Kyushu University Hospital), Masahiro Seike(Nippon Medical School Hospital), Yukari Tsubata(Shimane University), Hajime Asahina(Hokkaido University), Isamu Okamoto(Kyushu University Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Kazuhisa Takahashi(Kansai Medical University), Kentaro Tanaka(Institute for the Future), Satoshi Morita(Kyoto University), Ryo Morita(Akita Industrial Technology Center)
Cited by 27
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695